People · Operator
Named in public records as an officer, director or promoter · active 2009–2017 · Biotech / Pharma, Other, Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Coherus BioSciences, Inc. | — | Biotech / Pharma | Series C | $160.7M | $258.3M | 2013 |
| Viamet Pharmaceuticals Holdings LLC | — | Other | Series B | $74.6M | $199.4M | 2011 |
| Innocrin Pharmaceuticals Holdings, LLC | — | Pharmaceuticals | Series B | $42.1M | $204.0M | 2014 |
| Viamet Pharmaceuticals Inc | — | Pharmaceuticals | Series B | $35.0M | $850.1M | 2009 |
| Globeimmune Inc | — | Pharmaceuticals | Series B | $28.0M | $71.4M | 2013 |
| Cylene Pharmaceuticals, Inc. | — | Biotechnology | Series B | $22.6M | $34.4M | 2010 |
| Esanex, Inc. | — | Pharmaceuticals | Series B | $18.1M | $87.9M | 2012 |
| Trinity Biosystems Inc | — | Biotechnology | Series A | $14.9M | $271.1M | 2009 |
S Edward Torres at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside S Edward Torres on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.